Orser Capital Management LLC Invests $2.10 Million in Edwards Lifesciences Co. (NYSE:EW)

Orser Capital Management LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 28,982 shares of the medical research company’s stock, valued at approximately $2,101,000. Edwards Lifesciences makes up approximately 1.6% of Orser Capital Management LLC’s holdings, making the stock its 19th biggest holding.

A number of other hedge funds have also made changes to their positions in EW. Merit Financial Group LLC lifted its stake in Edwards Lifesciences by 93.4% during the first quarter. Merit Financial Group LLC now owns 10,793 shares of the medical research company’s stock worth $782,000 after purchasing an additional 5,212 shares during the last quarter. Harbor Investment Advisory LLC lifted its stake in Edwards Lifesciences by 26.3% during the first quarter. Harbor Investment Advisory LLC now owns 22,507 shares of the medical research company’s stock worth $1,631,000 after purchasing an additional 4,682 shares during the last quarter. Inspirion Wealth Advisors LLC lifted its stake in Edwards Lifesciences by 4.3% during the first quarter. Inspirion Wealth Advisors LLC now owns 11,763 shares of the medical research company’s stock worth $853,000 after purchasing an additional 488 shares during the last quarter. Czech National Bank lifted its stake in Edwards Lifesciences by 5.9% during the first quarter. Czech National Bank now owns 135,468 shares of the medical research company’s stock worth $9,819,000 after purchasing an additional 7,587 shares during the last quarter. Finally, Legacy Wealth Asset Management LLC lifted its stake in Edwards Lifesciences by 5.8% during the first quarter. Legacy Wealth Asset Management LLC now owns 21,960 shares of the medical research company’s stock worth $1,592,000 after purchasing an additional 1,207 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on EW shares. Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a research note on Friday, April 25th. Barclays upped their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Morgan Stanley upped their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $80.20.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $78.03 on Tuesday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $73.49 and its two-hundred day moving average price is $72.57. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25. The stock has a market cap of $45.77 billion, a PE ratio of 11.20, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. The firm had revenue of $1.41 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Edwards Lifesciences’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.66 earnings per share. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at $4,106,859.33. The trade was a 9.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of Edwards Lifesciences stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $77.40, for a total value of $198,918.00. Following the sale, the vice president now owns 50,356 shares of the company’s stock, valued at approximately $3,897,554.40. This represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 59,012 shares of company stock valued at $4,224,717 in the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.